When was Synnovation Therapeutics founded?

Synnovation Therapeutics was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Synnovation Therapeutics located?

Synnovation Therapeutics is headquartered in Delaware, United States.

How many employees does Synnovation Therapeutics have?

As of May 31, 2026, the latest employee count at Synnovation Therapeutics is 51.

Is Synnovation Therapeutics a funded company?

Synnovation Therapeutics is a funded company, having raised a total of $139M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 24, 2021.

When was the latest funding round of Synnovation Therapeutics?

Synnovation Therapeutics' latest funding was a $***** Series A round on Dec 08, 2023, with participation from 5 investors.

Where does Synnovation Therapeutics rank among its competitors?

Synnovation Therapeutics ranks 116th amongst 3299 active competitors, of which 1118 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Synnovation Therapeutics?

Synnovation Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Synnovation Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Synnovation Therapeutics is a series A company based in Delaware (United States), founded in 2021 by Wenqing Yao. It operates as a Developer of therapeutics for the treatment of cancer. Synnovation Therapeutics has raised $139M in funding from Third Rock Ventures. The company has 3299 active competitors, including 1118 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for the treatment of cancer. The company is focusing on the discovery and development of targeted therapies by leveraging deep expertise in medicinal chemistry, cancer biology, and patient-focused precision medicine.

Website: www.synnovationtx.com/
Email ID: *****@synnovationtx.com

Key Metrics

Founded Year

2021

Location

Delaware, United States

Stage

Series A

Total Funding

$139M in 3 rounds

Latest Funding Round

Series A, Dec 08, 2023, $*****

Investors

Third Rock Ventures & 4 more

Ranked

116^th among 3299 active competitors

Employee Count

51 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2983 more

View Synnovation Therapeutics' full profile

Synnovation Therapeutics has raised a total funding of $139M over 3 rounds. Its first funding round was on Nov 24, 2021. Its latest funding round was a Series A round on Dec 08, 2023 for $*****. 5 investors participated in its latest round. Synnovation Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Synnovation Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 08, 2023	6341861	Series A	9187283	4026999	4132920	1775661
May 24, 2023	6167505	Series A	9370792	5359065	3442597	6254585
Nov 24, 2021	7038797	Series A	1733063	4576907	5406592	5965949

Access funding benchmarks and valuations. Sign up today!

View details of Synnovation Therapeutics's funding rounds and investors

The founders of Synnovation Therapeutics is Wenqing Yao.

Here are the details of Synnovation Therapeutics' key team members:

Wenqing Yao: Co-Founder of Synnovation Therapeutics.
Contact Info: 1 email address

View details of Synnovation Therapeutics's Founder profiles and Board Members

Synnovation Therapeutics' employee count trend

Synnovation Therapeutics has 51 employees as of May 26. Here is Synnovation Therapeutics's employee count trend over the years:

Employee count trend for Synnovation Therapeutics

Uncover Synnovation Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Synnovation Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Synnovation Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
116th	Synnovation Therapeutics 2021, Delaware (United States), Series A	Developer of therapeutics for the treatment of cancer	$139M	Nextech Invest, Cormorant Asset Management ... & 3 others	61/100